On June 5, 2019, there was a patent about acute b-cell leukemia.Electric Literature of 64987-16-2 The title of the patent was Preparation of substituted sulfonamidothiazoles as CTRS1 inhibitors. And the patent contained the following:
The invention relates to compounds of formula I (wherein R1 is (un)substituted C1-5 alkyl and C0-2 alkyleneC3-5 cycloalkyl; R3 is H, halo, CH3, etc.; R4 and R5 are independently H, halo, C1-6 alkyl, etc.; R6 is H and C1-3 alkyl, etc.; Ar1 is 6-membered aryl and heteroaryl; Ar2 is 6-membered aryl and heteroaryl; R10 is H, halo, C1-3 alkyl, etc.; R11 is H, F, Cl, Me, etc.; R12 is H, halo, C1-4 alkyl, etc.; R13 is H, halo, Me and OMe;) and salts, solvates thereof and derivatives thereof, their preparation and use as CTR synthase 1 inhibitors for the treatment of disorders associated with cell proliferation. Example compound II was prepared by cross-coupling of N-(4-bromophenyl)-2-(2-(cyclopropanesulfonamido)thiazol-4-yl)-2-methylpropanamide with pyrimidin-5-ylboronic acid. The invention compounds were evaluated for their CTRS1 inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of ≤ 1μM. The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Electric Literature of 64987-16-2
The Article related to sulfonamidothiazole preparation ctrs1 inhibitor treatment cell proliferation, acute b-cell leukemia and other aspects.Electric Literature of 64987-16-2
Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica